The final approval in the Senate of a new law on obesity marks a historic turning point for Italy: obesity is officially recognised as a chronic, progressive, and relapsing disease requiring prevention, early diagnosis, and integrated care. https://t.co/7VMoXJvcYE

By 2030, 80% of the EU population may be living with obesity, driving healthcare costs and highlighting the urgent need for coordinated, strategic action across Europe. Download the full policy recommendation document. https://t.co/L1yFOKw8wu

Join Prof Dror Dicker tomorrow for the EASOCOMs Network webinar: MASLD and Obesity: Mechanisms and Management 🗓️ Tues 28 Oct 2025 at 11:30am UK / 12:30pm Paris Register here: https://t.co/mBaww517Dx @EASOobesity

Congratulations to the SWEET project team on the publication of their important new study, “Effect of sweeteners and sweetness enhancers on weight management and gut microbiota composition in individuals with overweight or obesity: the SWEET Study,” https://t.co/LHrE26w4vu

Semaglutide or tirzepatide should be first-line medications for obesity and most of its related complications, new guidance from @EASOobesity @AndreeaCiudin1 https://t.co/PuSY7R7NAD

Projections that 80% of the EU population will be living with obesity by 2030, alongside the already substantial healthcare costs linked to obesity-related conditions, underline the urgent need for coordinated, strategic action across Europe. https://t.co/L1yFOKw8wu #EASOPolicy

Nominations for the Prestigious Obesity Prize for Excellence are now open! 🏆 This award recognises outstanding research or technological contributions to understanding obesity, its aetiology, complications, prevention and treatment. https://t.co/cCO5tsTgge @novonordiskfond

EASO was pleased to participate in the RC75 side event: Strengthening Health Security: Planning Through Evidence and Risk-Based Approaches. Addressing obesity is essential for resilient health systems and reducing vulnerability to future health crises. https://t.co/64vN1TMUal

Applications for the 2026 EASO-@novonordiskfond New Investigator Awards in Basic Science, Clinical Research, Public Health & Childhood Obesity are now open! ✅ Each winner will be supported to attend and speak at the special award session at #ECO2026. https://t.co/gVIMrQqqBE

A new insights report, commissioned by West Yorkshire Integrated Care Board (ICB) UK explores the human, social, and financial impact of obesity across the region, revealing a need for a more connected system of care. https://t.co/x0L5bZcQ26

Meet @EASOobesityECN board member - Dr Rebecca Evans, Postdoctoral Researcher from the UK.🇬🇧 Her research predominantly focuses on public health, specifically environmental factors influencing eating behaviour. Learn more: https://t.co/pR8u2D9nvR

Call for Abstracts from researchers from across the globe: Abstract submissions are now open for the European Congress on Obesity #ECO2026, which will take place in Istanbul, Türkiye, 12-15 May 2026. 🇹🇷 Deadline for submissions: 11 January 2026 https://t.co/fQZm6uoAjM

Join Barbara McGowan and learn how the new EASO algorithm is transforming obesity care by guiding clinicians to match pharmacotherapy to individual obesity-related complications, not just weight loss. https://t.co/VsDMbycJU9

The @EASOobesityECN board invites members to the next online event in the eLearning Hub series: Designing Child-Centred Health Promotion Interventions. ✔️Mario Silva and Raquel Martins will share real-life examples. 👉14th Oct - 4pm UK / 5pm Paris https://t.co/4MTKAF4xmp

Semaglutide or tirzepatide should be the first-line pharmacological treatment for people living with obesity and most of its complications, according to our new framework for the pharmacological treatment of obesity and its complications @AndreeaCiudin1 https://t.co/ug7IjYHvlh

Introducing @EASOobesityECN board member - Beatriz Farinha, PhD student in Biomedicine from 🇪🇸 Learn more about her research exploring how adipose tissue fibrosis and extracellular matrix remodelling contribute to obesity-associated liver diseases. https://t.co/jrhF4jPHCn

📢We are pleased to announce publication of the EASO Algorithm for the pharmacological treatment of obesity and its complications in Nature Medicine. Obesity is an adiposity-based chronic disease (ABCD); assess severity and complications to guide treatment https://t.co/gCyRv9eTsG

Today is World Heart Day 2025. #CVD is the world’s leading killer – and obesity is a major cause of CVD. EASO has contributed to the EU Cardiovascular Health Plan to ensure obesity is recognised as central to improving heart health. Learn more: https://t.co/39eBoLTxkS

Niamh Arthurs invites early-career professionals looking to connect and collaborate on projects and share experiences and expertise, to join the @EASOobesity Early Career Network https://t.co/i88rsxY3Go @BiaBites #dietitians #endocrinologists #nurses @EASOobesityECN

EASO was pleased to represent Europe at ICOMES 2025 in Seoul 🇰🇷 @EASOPresident Prof. Volkan Yumuk and President-Elect Prof. Jennifer Baker joined the joint KSSO–EASO symposium on advances in pharmacological and individualised obesity care. Read more: https://t.co/1G085L2s9e